CONTEXT: Real-world study from Japan showing increased rates of pneumonitis with first-line pembrolizumab plus chemotherapy in patients with advanced NSCLC. IMPACT: Medium READ TIME: 2 mins Quality Level Mean [1 Continue Reading
CONTEXT: Worth checking out the original peer-reviewed poster presented at this years AMCP conference. The research notes where RWD source are not comprehensive enough to help answer research questions and Continue Reading
CONTEXT: Another RWR study showing deficiencies in available biomarker testing, this time in Chronic lymphatic leukaemia patients. Biomarker driven care will give better outcomes for those patients with specific mutations Continue Reading
CONTEXT: It’s awards season and as we wait to see who will be glammed up from the waist up at the Oscars, another RWE report is issued with even bigger Continue Reading
CONTEXT: On the back of previous news stories about genetic biomarker testing in NSCLC, Neogenomics announces the launch of KRAS G12C testing to eligible advanced / late stage NSCLC cancer Continue Reading
CONTEXT: A proper peer reviewed study article on a retrospective study based on an oncology registry in Canada highlighting the differences in outcomes for rural versus urban patients. READ TIME: Continue Reading
CONTEXT: Oncology news article on use of RWR in oncology. Nothing new in terms of data use, more confirmation of RWD in oncology research. However, an interesting perspective from the Continue Reading
Comments – Part of the growing trend for big pharma to secure bid data sources for their own use. A move in the right direction towards ‘regulatory grade’ RWE. READ Continue Reading
COMMENTS: Good story on use of RWE / RWR in oncology. READ TIME: 2 mins *1. “Sir Mick Peake, clinical director for the Centre for Cancer Outcomes within UCLH’s Cancer Continue Reading
COMMENTS: Part of the growing trend for big pharma to secure bid data sources for their own use. IMPACT: A move in the right direction towards ‘regulatory grade’ RWE, READ Continue Reading
